What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: Copaxone
97%DGNews: New Drug for Multiple Sclerosis Now Available
96%DGNews: REVISED: Glatiramer Acetate Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When interferon beta-1a Failed
96%DGNews: Long-Term Glatiramer Acetate Injection Study Showed 92% of Multiple Sclerosis Patients Were Walking Unaided After a Mean of 10 Years on Treatment
96%DGNews: Copaxone (Glatiramer Acetate) Demonstrated Protection Against Neuronal Injury In Relapsing-Remitting Multiple Sclerosis
96%DGNews: Copaxone (Glatiramer Acetate Injection) May Protect Against Axonal Injury Over the Long-Term in Relapsing-Remitting Multiple Sclerosis
96%DGNews: Copaxone (Glatiramer Acetate) Reduces Brain Atrophy in Patients with Multiple Sclerosis
96%DGNews: Early Treatment Of Multiple Sclerosis With Copaxone (Glatiramer Acetate) Delays Accumulation Of Additional Brain Lesions
96%DGNews: Sustained Immunological Effects Of Copaxone (Glatiramer Acetate Injection) In Patients With MS Treated Over Six Years
96%DGNews: New Pre-Filled Syringe For Copaxone® Users Makes Injection Process Easier
96%DGNews: AAN: Early Copaxone (Glatiramer Acetate) Could Decrease Permanent Multiple Sclerosis Disability
96%DGNews: Copaxone (Glatiramer Acetate) Reduces Number Of Relapses In Relapse-Remitting Multiple Sclerosis
96%DGNews: COPAXONE Cleared by FDA for Multiple Sclerosis
95%DGNews: Glatiramer Acetate Injections Reduced Relapses by 75% in Both Treatment-Naïve Multiple Sclerosis Patients and Those Failing Interferon Beta-1b
95%DGNews: AAN: Copaxone (Glatiramer) Effective in Reducing Multiple Sclerosis Progression Over 10 Years, Study to be Extended
95%DGNews: Clinical Effects of Copaxone (Glatiramer) or Interferon Therapy Compared to Untreated Patients with Relapsing-Remitting Multiple Sclerosis
95%DGNews: Copaxone (glatiramer acetate injection) Effective In Relapsing-Remitting Multiple Sclerosis Regardless Of Disease Severity
95%DGNews: ENS: Study Shows Benefit Of Switch To Copaxone (Glatiramer Acetate Injection) For Multiple Sclerosis Patients
95%DGNews: Multiple Sclerosis Drug, Copaxone (Glatiramer Acetate), Does Not Generate Neutralizing Antibodies
95%DGNews: Copaxone Does Not Increase Headache In Multiple Sclerosis Patients
95%DGNews: AAN: Copaxone (Glatiramer) Shows Significant, Long-Term Benefit in Multiple Sclerosis
95%DGNews: Copaxone (Glatiramer) Available In UK For Relapsing-Remitting Multiple Sclerosis
95%DGNews: Sustained Use Of Copaxone (Glatiramer Acetate) Reduces Relapse Rate In Multiple Sclerosis
95%DGNews: The U.K. Approves Copaxone (Glatiramer Acetate) For Relapsing-remitting Multiple Sclerosis
94%DGNews: Researchers Discover Potential Neuroprotection Properties For Copaxone (Glatiramer Acetate Injection)
94%DGNews: Copaxone Shown to Reduce "Black Holes" in Brain
94%DGNews: Multiple Sclerosis Drug Copaxone (Glatiramer Acetate) Reduces Relapses, Sustains Efficacy
94%DGNews: MS Society Recommends Early Drug Therapy
94%DGNews: Copaxone Slows Progression Of Disability, Reduces Relapses In MS
93%DGNews: Three-Year Study Shows Good Efficacy and Safety for Copaxone in MS: Presented at ECTRIMS
93%DGNews: Copaxone (Glatiramer acetate) and Betaseron® (Interferon beta-1b) Yield Statistically Significant Results In Relapsing-Remitting Multiple Sclerosis
93%DGNews: Copaxone (Glatiramer Acetate) Shown to Reduce Brain Lesions In Multiple Sclerosis
93%DGNews: New Treatment Approved for Multiple Sclerosis
93%DGNews: Copaxone Approved In Switzerland For Relapse-Remitting Multiple Sclerosis
92%DGNews: Scientists Identify Genes Affecting MS Patient Response to Copaxone
92%DGNews: DG Dispatch - AAN: MRI Scan Shows Fewer Brain Lesions In MS Patients Taking Copaxone
91%DGNews: READY Trial: Belief in Ability to Self-Inject Copaxone (Glatiramer Acetate) Appears 'Paramount' to Adherence in MS Patients: Presented at ECTRIMS
91%DGNews: Long-Term Use of Glatiramer Acetate (Copaxone) for Multiple Sclerosis Appears Safe and Efficacious: Presented at ECTRIMS
91%DGNews: ANA: Copaxone, Betaseron Effective But No Statistically Significant Effect for Avonex
89%DGNews: No Evidence That Glatiramer Acetate Slows Multiple Sclerosis Progression
87%DGNews: Glatiramer Acetate (Copaxone) Safe for Paediatric Multiple Sclerosis: Presented at ECTRIMS
85%DGNews: Health Canada Approves Glatiramer Acetate for Clinically Isolated Syndrome Suggestive of MS
85%DGNews: FDA Approves Glatiramer Acetate for Symptoms Suggestive of MS
85%DGNews: Glatiramer Acetate Approved for Patients With Clinical Isolated Syndrome Suggestive of MS
85%DGNews: Noncompliance With Multiple Sclerosis Therapy Appears Treatment Related, Affects Quality of Life: Presented at ECTRIMS
85%DGNews: Early Use of Glatiramer Acetate May Mitigate Course of Disease in Multiple Sclerosis: Presented at ENS
85%DGNews: Once-Weekly Avonex Shows Better Patient Compliance Than Other MS Treatments
84%DGNews: Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS
83%DGNews: Could Estriol Be the Elixir for MS?
81%DGNews: No Differences Found Between Interferon Beta-1b and Glatiramer for Multiple Sclerosis: Presented at ECTRIMS
80%DGNews: Treatment with Glatiramer Acetate Linked to Greater Disease Stability in Early Multiple Sclerosis: Presented at ENS
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.